You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

Details for Patent: 10,119,143

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,119,143 protect, and when does it expire?

Patent 10,119,143 protects GIVLAARI and is included in one NDA.

This patent has seventy-one patent family members in thirty-eight countries.

Summary for Patent: 10,119,143

Patent landscape, scope, and claims:

Title:	Compositions and methods for inhibiting expression of the ALAS1 gene
Abstract:	The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.
Inventor(s):	Bettencourt; Brian (Groton, MA), Fitzgerald; Kevin (Brookline, MA), Querbes; William (Cambridge, MA), Desnick; Robert J. (New York, NY), Yasuda; Makiko (New York, NY)
Assignee:	ALNYLAM PHARMACEUTICALS, INC. (Cambridge, MA) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (New York, NY)
Application Number:	15/027,176
Patent Claim Types: see list of patent claims	Use; Composition; Compound;
More… ↓ ⤷ Subscribe

Drugs Protected by US Patent 10,119,143

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Alnylam Pharms Inc	GIVLAARI	givosiran sodium	SOLUTION;SUBCUTANEOUS	212194-001	Nov 20, 2019		RX	Yes	Yes	⤷ Subscribe	⤷ Subscribe	Y	Y		TREATMENT OF ACUTE HEPATIC PORPHYRIA	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 10,119,143

PCT Information
PCT Filed	October 03, 2014	PCT Application Number:	PCT/US2014/059160
PCT Publication Date:	April 09, 2015	PCT Publication Number:	WO2015/051318

International Family Members for US Patent 10,119,143

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3052628	⤷ Subscribe	301061	Netherlands	⤷ Subscribe
European Patent Office	3052628	⤷ Subscribe	LUC00175	Luxembourg	⤷ Subscribe
European Patent Office	3052628	⤷ Subscribe	122020000045	Germany	⤷ Subscribe
European Patent Office	3052628	⤷ Subscribe	PA2020527	Lithuania	⤷ Subscribe
European Patent Office	3052628	⤷ Subscribe	2020C/532	Belgium	⤷ Subscribe
European Patent Office	3052628	⤷ Subscribe	CA 2020 00042	Denmark	⤷ Subscribe
European Patent Office	3052628	⤷ Subscribe	37/2020	Austria	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.